Alnylam Pharmaceuticals (ALNY) Operating Margin Growth (1y) (2010 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) Operating Margin Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 602.00 |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -16,814.00 |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | -143.00 |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 78.00 |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 1,135.00 |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 7,666.00 |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 2,002.00 |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -2,881.00 |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 29,091.00 |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -70,568.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2,002.00 |
| Mar 31, 2026 | -3,724.00 |
| Dec 31, 2025 | 2,974.00 |
| Sep 30, 2025 | 4,481.00 |
| Jun 30, 2025 | -946.00 |
| Mar 31, 2025 | 6,904.00 |
| Dec 31, 2024 | 874.00 |
| Sep 30, 2024 | -4,385.00 |
| Jun 30, 2024 | 7,947.00 |
| Mar 31, 2024 | 3,813.00 |
| Dec 31, 2023 | 2,982.00 |
| Sep 30, 2023 | 12,612.00 |
| Jun 30, 2023 | 1,316.00 |
| Mar 31, 2023 | 2,189.00 |
| Dec 31, 2022 | 1,896.00 |
| Sep 30, 2022 | -80.00 |
| Jun 30, 2022 | -1,899.00 |
| Mar 31, 2022 | 3,609.00 |
| Dec 31, 2021 | 4,349.00 |
| Sep 30, 2021 | 8,211.00 |